FDA Warning Letters to Foreign Facilities: What They Mean and How to Respond

An FDA Warning Letter is one of the most serious communications a foreign manufacturer can receive from the United States government. It is a formal notification that the FDA has identified significant violations of the Federal Food, Drug, and Cosmetic Act or its implementing regulations at your facility, and that the agency expects prompt corrective action. Warning Letters are not administrative formalities — they are public documents posted on the FDA's website for anyone to see, they signal to your US importers and customers that your facility has compliance problems, and they set the clock on a response deadline that, if missed, can trigger escalating enforcement actions including import alerts, injunctions, seizures, and criminal prosecution.

What triggers a Warning Letter

Warning Letters typically result from one of several scenarios. The most common trigger is an FDA facility inspection that identifies significant CGMP violations documented in Form FDA 483 observations, followed by an inadequate or absent response from the facility. Warning Letters are also issued based on review of product labels, marketing materials, or websites that contain drug claims on cosmetic or food products, based on adverse event reports that suggest systematic safety problems, based on test results from FDA sampling programs that identify adulteration or contamination, or based on intelligence from other regulatory authorities or whistleblowers. The decision to issue a Warning Letter involves review by the FDA district office, the relevant Center (CFSAN for food and cosmetics, CDER for drugs, CDRH for devices), and the Office of Regulatory Affairs.

The 15-business-day response deadline

A Warning Letter specifies a response deadline — typically 15 business days from the date of the letter. The response must address each violation identified in the letter with specific corrective actions, including what has been done (or will be done) to correct the violation, a root cause analysis explaining why the violation occurred, preventive measures to ensure the violation does not recur, and a timeline for implementation of each corrective action. Generic responses that promise to 'review procedures' or 'improve systems' without specifying concrete actions are considered inadequate. The FDA evaluates the response and determines whether the corrective actions are sufficient to resolve the violations.

Consequences of not responding or responding inadequately

If a foreign facility does not respond to a Warning Letter, or responds inadequately, the FDA can escalate enforcement. The most common escalation for foreign facilities is placement on an import alert, which results in Detention Without Physical Examination (DWPE) of all products from the facility at US ports. Import Alert 99-40 is commonly used for facilities with significant CGMP violations. The FDA can also seek injunctions in federal court, seize products already in US commerce, or refer the case for criminal prosecution. For drug manufacturers, an unresolved Warning Letter can also affect the approval of pending drug applications — the FDA may refuse to approve an NDA or ANDA from a facility with outstanding CGMP violations.

Warning Letters are public records

Every Warning Letter is published on the FDA's website and is searchable by company name, product type, and violation category. This public posting has significant business consequences beyond the regulatory enforcement itself. US importers, retailers, and distributors routinely check the FDA Warning Letter database when evaluating potential suppliers, and a Warning Letter can result in the loss of existing US customers and the inability to find new ones. The reputational impact extends beyond the US market — regulatory authorities in other countries, certification bodies, and international customers may also review FDA Warning Letters when making sourcing or audit decisions. Warning Letters remain visible on the FDA website for at least five years after the close-out letter is issued.

How to achieve close-out of a Warning Letter

A Warning Letter is closed out when the FDA determines that the violations have been adequately corrected. This may require a follow-up inspection (for violations identified during a facility inspection), submission of documentary evidence of corrective actions, or a combination of both. The close-out process can take months or years, depending on the severity of the violations and the completeness of the corrective actions. When the FDA is satisfied that the violations have been resolved, it issues a close-out letter, which is also posted on the FDA website. Between the Warning Letter and the close-out, the facility's products may face heightened scrutiny, import holds, or other restrictions.

How FDABridge helps facilities maintain compliance

FDABridge provides registration, US Agent, and compliance support services that help foreign facilities maintain their regulatory standing with the FDA and avoid the compliance gaps that can lead to Warning Letters. Our US Agent service ensures that FDA communications — including inspection notices, inquiries, and enforcement correspondence — are received and forwarded promptly. Visit fdabridge.com to see our services or fdabridge.com/contact to speak with our team.